Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 3.770
+0.090 (2.45%)
Jun 11, 2026, 5:29 PM CET
Sprint Bioscience AB Market Cap
Sprint Bioscience AB has a market cap or net worth of 397.79 million as of June 11, 2026. Its market cap has increased by 812.83% in one year.
Market Cap
397.79M
Enterprise Value
289.46M
Revenue
153.28M
Ranking
n/a
PE Ratio
4.57
Stock Price
3.77
Market Cap Chart
Since November 7, 2014, Sprint Bioscience AB's market cap has increased from 62.49M to 397.79M, an increase of 536.53%. That is a compound annual growth rate of 17.30%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 10, 2026 | 388.30M | 150.34% |
| Dec 30, 2025 | 155.11M | 40.43% |
| Dec 30, 2024 | 110.46M | -8.82% |
| Dec 29, 2023 | 121.14M | 449.78% |
| Dec 30, 2022 | 22.03M | -88.47% |
| Dec 30, 2021 | 191.05M | 17.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| FluoGuide | 753.70M |
| SynAct Pharma AB | 734.35M |
| Oncopeptides AB | 671.99M |
| AlzeCure Pharma AB | 590.66M |
| Cantargia AB | 522.08M |
| Corline Biomedical AB | 469.09M |
| Intervacc AB | 434.20M |
| Ascelia Pharma AB | 385.92M |